Cancer Immunology and Immunotherapy
A section of Cancers (ISSN 2072-6694).
Section Information
Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for advanced cancer. Understanding the common mechanisms of tumorigenesis, including changes in tumor microenvironment, immune evasion, and antitumor immune responses, is pivotal for further development of novel therapeutics.
Following early discoveries of connection of autoimmune diseases with cancer, recent advances in T cell biology have revolutionized cancer therapy. Most importantly, standard-of-care chemotherapy and radiation effects have also been linked to immune cell-mediated anticancer effects.
Importantly, multiple clinical trials using checkpoint blockade agents, ATC transfer therapies, and cancer vaccines show much better outcomes than the most effective chemotherapeutic agents.
The aim of this Special Section is to publish findings that relate to cancer immunology and therapies based on the immune-targeting. Topics include, but are not limited to:
- checkpoint blockade
- innate immunity
- adaptive responses
- vaccines
- ATC transfer therapy
- immune evasion
- immune switch
- immunosuppression
- tumor microenvironment
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Advances in Immunotherapy, Biomarkers, and Clinical Practice in Pleural Mesothelioma and Thoracic Cancers (Deadline: 30 October 2026)
- Mechanisms of Resistance and Response to Immune Checkpoint Inhibitors in Squamous Cell Carcinomas (Deadline: 31 October 2026)
- Opportunities and Challenges for Effective Cancer Immunotherapies (Deadline: 31 October 2026)
- Cellular Immunotherapy for Hematological Malignancies (Deadline: 1 November 2026)
- Immune Cells Within the Tumor Microenvironment (Deadline: 3 November 2026)
- Novel Insights into Glioma Immunotherapy (Deadline: 5 November 2026)
- Immunotherapy with Checkpoint Inhibitors for Non-Small-Cell Lung Cancer (2nd Edition) (Deadline: 30 December 2026)
- Cancer Immunotherapy in Clinical and Translational Research (2nd Edition) (Deadline: 31 December 2026)
- Gene Regulation and Immune Checkpoints in Cancer Immunotherapy: Mechanisms and Therapeutic Opportunities (Deadline: 31 December 2026)
- Advancing CAR-T Cell Therapy: The Next Evolution in Breast Cancer Treatment (Deadline: 15 January 2027)
- Precision Oncology and Immunotherapy in Bone and Soft Tissue Sarcomas (Deadline: 31 January 2027)
- The Future of Cancer Immunotherapy: Biomarkers, Tumor Microenvironment, and Precision Medicine (Deadline: 31 January 2027)
- Immunotherapy for Hematologic Malignancies (Deadline: 15 February 2027)
- Advances in the Immunotherapy of Metastatic Cancer (Deadline: 20 February 2027)
- CAR T Cell Therapy in Cancer: Progress and Challenges Across Solid and Hematologic Malignancies (Deadline: 28 February 2027)
- Neoantigen Vaccines for Cancer Therapy (Deadline: 28 February 2027)
- Innovative Immunotherapies: CAR-T Cell Therapy for Cancers: 2nd Edition (Deadline: 9 April 2027)
- The Relationship Between Cancers Metabolism and Immunotherapy (Deadline: 30 April 2027)
- The Role of Immune Checkpoint Inhibitors in Cancer Therapy (Deadline: 30 April 2027)
- Combination Immunotherapy for Cancer Treatment—2nd Edition (Deadline: 20 May 2027)
- Cancer Immunotherapy-Related Adverse Events and Therapy-Related Accelerated Aging (Deadline: 30 June 2027)
- Gene Regulation of Immune Checkpoints in Cancer Immunotherapy (Deadline: 25 July 2027)
- Multi-Omics and AI-Driven Precision Stratification in Cancer Immunotherapy (Deadline: 31 July 2027)
- T Cells in Hematologic Malignancies: Biology, Microenvironment, and Therapeutic Advances (Deadline: 16 September 2027)
- Immunological Aspects of Lynch Syndrome (Deadline: 30 September 2027)
